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MicroRNA alterations and axonopathy have been
reported in patients with Alzheimer’s disease (AD)
and in AD mouse models. We now report that miR-
342-5p is upregulated in APP/PS1, PS1DE9, and
PS1-M146V transgenic AD mice, and that this upre-
gulation is mechanistically linked to elevated b-cate-
nin, c-Myc, and interferon regulatory factor-9. The
increased miR-342-5p downregulates the expres-
sion of ankyrin G (AnkG), a protein that is known to
play a critical role at the axon initial segment. Thus,
a specific miRNA alteration may contribute to AD
axonopathy by downregulating AnkG.INTRODUCTION
MicroRNAs (miRNAs) are a class of short (usually 21–23 nt) non-
coding RNAs (Lagos-Quintana et al., 2001) with conserved roles
in Drosophila, rodents, monkeys, and humans (Ashraf et al.,
2006; Elme´n et al., 2008; Hollander et al., 2010; Jin et al.,
2004); in mammals, over 1,000 miRNAs have been identified
(Delay et al., 2012). miRNA precursors are first processed into
a single-stranded miRNA that interacts with the 30 UTR of the
complementary mRNA sequences (Peters and Meister, 2007),
resulting in translation repression or target degradation (Eulalio
et al., 2009; Meister, 2007). A single miRNA can have up to
several hundred target genes and thus may regulate multiple
pathways at the same time (Baek et al., 2008; Selbach et al.,
2008). Many miRNAs have demonstrated implications in neuro-
degenerative diseases, such as Alzheimer’s disease (AD) (Chan
and Kocerha, 2012; Delay and He´bert, 2011; Delay et al., 2012),
which is the most common cause of dementia in people over 65
years of age and is associated with impairments in memory,
language, behavior, and cognition (Price et al., 1995).
The brains of patients with AD are characterized by the pres-
ence of senile plaques and neurofibrillary tangles (Price et al.,
1995), together with axonal pathology involving dystrophic
neurites decorating amyloid plaques, axonal swellings, and
abnormal accumulation of axonal proteins (Bayer et al., 2001).
Axonopathy and axonal transport deficits have been found in264 Cell Reports 6, 264–270, January 30, 2014 ª2014 The Authorsother neurodegenerative diseases as well (Roy et al., 2005;
Yagishita, 1978). In this regard, abundant age-dependent axonal
spheroids and myelin ovoids have been observed in the spinal
cord of APP/PS1 mice, an established AD transgenic mouse
model (Wirths et al., 2006). However, the cause of the axonop-
athy and the pathways involved in axonal abnormalities in AD
remain largely unknown. The axon initial segment (AIS) is known
to play an important role in neuronal polarity formation, action
potential initiation (Rasband, 2010; Szu-Yu Ho and Rasband,
2011), and brain diseases and injury (Buffington and Rasband,
2011). Ankyrin G (AnkG) has been demonstrated to play an
important role in maintaining the structure of AIS and in the gen-
eration/maintenance of neuronal polarity (Hedstrom et al., 2008;
Kapfhamer et al., 1995; Kordeli et al., 1995; Sobotzik et al., 2009).
AnkG was found to link membrane proteins to the cytoskeleton
and play critical roles in the stabilization of membrane domains
(Bennett and Chen, 2001) and neuronal polarity (Sobotzik
et al., 2009). Neuronal injury could result in the loss of AnkG
(Schafer et al., 2009). At the AIS, the critical function of AnkG
has been reported to mediate sodium channel localization (Pan
et al., 2006) and the establishment of selective filtering machin-
ery (Song et al., 2009).
In the present study, we report that in APP/PS1, PS1DE9,
and PS1-M146V mouse hippocampal neurons, miR-342-5p, a
miRNA that targets AnkG mRNA 30 UTR, is highly upregulated
compared with wild-type (WT) mouse neurons. Furthermore,
we show that downregulation of AnkG by miR-342-5p is medi-
ated through translation repression. Our results point to miRNA
regulation as a critical determinant of axonal and neuronal
pathology in AD mouse models.RESULTS
Upregulation of miR-342-5p in the Hippocampus of AD
Transgenic Mice
Microarray analysis of miRNAs was performed on pooled hippo-
campal tissues from WT (n = 16) and APP/PS1 mice (n = 16) at
embryonic day 14 (E14). Our data showed that, with the criterion
of a 2-fold cutoff, seven miRNAs were upregulated (Figure 1A,
red dots) and seven miRNAs were downregulated (green dots)
in APP/PS1 hippocampal tissues as compared with WT hippo-
campal tissues. Among these altered miRNAs, miR-342-5p
Figure 1. miR-342-5p Was Upregulated in APP/PS1, PS1DE9, and PS1-M146V Mice
(A) A miRNA array assay was done with hippocampal tissues from E14 WT (n = 16, pooled) and APP/PS1 (n = 16, pooled) mice. One of miRNAs that showed a
significant increase in APP/PS1 mice was miR-342-5p.
(B) Left panel: miR-342-5p increased 30-fold in the hippocampal tissues from APP/PS1 mice as compared with WT mice at 0, 2, and 4 months of age. Middle
and right panels: miR-342-5p was secreted via an unknown mechanism and detected in the CSF and plasma. In CSF and plasma from APP/PS1 mice, miR-342-
5p was upregulated at 0, 2, and 4 months of age compared with WT mouse samples.
(C) Left panel: increased miR-342-5p was found in E14 APP/PS1, PS1DE9, and PS1-M146V neurons, but not in APPswe or WT human PS1 (hPS1) transgenic
mouse neurons, indicating that in PS1 a mutation contributed to the APP/PS1 phenotype upon miR-342-5p alteration. Right panel: miR-342-5p levels were
significantly higher in the CSF and plasma of newborn APP/PS1, PS1DE9, and PS1-M146V mice, but not in APPswe or hPS1 mice. Data represent mean ± SE
(n = 10 for each group). **p < 0.01 compared with controls.was prominently increased and showed an 22-fold upregula-
tion in APP/PS1 hippocampus (Figure 1A). This upregula-
tion was further verified by RT-PCR measurements of the
miR-342-5p level in hippocampal tissues from WT and APP/
PS1 mice at 0, 2, and 4 months of age (Figure 1B). Previous
studies have shown that miRNAs can be secreted into the
cerebrospinal fluid (CSF) and plasma (Chan and Kocerha,
2012). In this regard, we observed that miR-342-5p levels
were elevated in the CSF and plasma of APP/PS1 samples
compared with WT samples collected at 0, 2, and 4 months of
age (Figure 1B).
Since APP/PS1 mice harbor transgenes encoding the familial
AD (FAD)-linked APPswe and PS1DE9 polypeptides, we sought
to examine changes in miR-342-5p in transgenic mice express-
ing the genes individually (APPswe, human WT PS1 [hWTPS1],
or PS1DE9), together with an independent transgenic line ex-
pressing the FAD-linked PS1-M146V variant. Interestingly, we
found that miR-342-5p was selectively upregulated in all PS1
mutant lines compared with the hWTPS1 and APPswe mutant
lines (Figure 1C). The increase in the miR-342-5p level was
confirmed in the CSF and plasma in the single-gene transgenic
lines as well (Figure 1C).
AnkG mRNA 30 UTR Was a Target of miR-342-5p
Complementary sequences for miR-342-5p are present in the
30 UTR of AnkG mRNA in both mouse and human (Figure S1A).
In SH-SY5Y cells, luciferase reporter assays were performed
with the expression of firefly regulated by the AnkG mRNA
30 UTR complementary region to miR-342-5p, and renilla as anCinternal control for transfection efficiency. We found that miR-
342-5p induced a dose-dependent inhibition of luciferase activ-
ity, whereas mutant miR-342-5p and scramble control (Scr)
miRNA had no effect (Figure 2A). The mimic of miR-342-5p
markedly inhibited the luciferase activity, whereas the inhibitor
of miR-342-5p increased the luciferase activity (Figure 2A). A
time-course study showed that miR-342-5p inhibited luciferase
activity from 6 to 48 hr after treatment (Figure 2B). In SH-SY5Y
cells, an enhanced GFP (EGFP) reporter assay confirmed that
miR-342-5p had a similar inhibitory effect on AnkG mRNA
30 UTR (Figures S1C and S1D).
We then mutated the AnkG mRNA 30 UTR complementary
sequence and performed luciferase assays with either Scr
miRNA or miR-342-5p. Our results indicated that miR-342-5p
suppressed the luciferase activity with WT AnkG mRNA
30 UTR, but not with mutant 30 UTR (Figures 2C and S1E), sug-
gesting the specificity of the interaction between miR-342-5p
and AnkG mRNA 30 UTR. To further validate that the AnkG
mRNA 30 UTR was one of the targets for miR-342-5p, we
made mutant AnkG mRNA 30 UTR with two repeats of the
putative complementary binding domain (BD) sequence (2BD)
and three repeats of the BD sequence (3BD). The luciferase
reporter system showed that miR-342-5p did not suppress
the luciferase activity regulated by unrelated MAP2 mRNA
30 UTR (Figure 2C). With AnkG mRNA 30 UTR, luciferase activity
was greatly reduced in a BD-dose-dependent manner (Fig-
ure 2C). To examine the specificity of miR-342-5p targeting
AnkG mRNA, we tested all seven miRNAs upregulated in
APP/PS1 tissues, as detected by microarray assay (Figure 1A),ell Reports 6, 264–270, January 30, 2014 ª2014 The Authors 265
Figure 2. miR-342-5p Regulated AnkG mRNA 30 UTR and Decreased AnkG Expression
(A) Dose response of miR-342-5p on luciferase reporter assay in SH-SY5Y cells.
(B) Time course of miR-342-5p inhibition on AnkG mRNA 30 UTR.
(C) Left panel: miR-342-5p reduced the luciferase activity withWT AnkGmRNA 30 UTR, but not with mutant AnkGmRNA 30 UTR. Right panel: miR-342-5p did not
alter the expression with unrelated MAP2 mRNA 30 UTR. With AnkG mRNA 30 UTR constructed with a 2- or 3-fold greater amount of the putative binding domain
(2BD or 3BD), miR-342-5p decreased luciferase activity remarkably in a BD dose-dependent manner.
(D) Other miRNAs pulled out in the miRNA array assay were tested against luciferase activity driven by AnkG mRNA 30 UTR. Only miR-342-5p specifically
decreased luciferase activity. Data represent mean ± SE (n = 10 for each group). **p < 0.01 compared with controls.
(E) Western blot of AnkG, using the antibody provided by Dr. V. Bennett (Duke University), shows that the mimic of miR-342-5p (lane 2) reduced the AnkG levels,
whereas the inhibitor of miR-342-5p (lane 3) increased them. Mutant miR-342-5p (lane 4) did not alter the AnkG levels. Data represent mean ± SE (n = 3 for each
group). **p < 0.01 compared with control.
(F) The RNase protection assay shows that in the mixture of AnkG mRNA 30 UTR with miR-342-5p (lane 4), the negative control antisense reversed sequence
(miR-342-5p, lane 3) and the positive control synthesized complementary sequence (miR-342-5p, lane 2) effectively protected AnkG mRNA 30 UTR from RNase
digestion (*), suggesting direct binding of miR-342-5p with AnkG mRNA 30 UTR. Lane 1: molecular weight marker.against luciferase reporter activity regulated by AnkG mRNA
30 UTR. Only miR-342-5p effectively inhibited luciferase activity
(Figure 2D).
When different concentrations of miR-342-5p were trans-
fected into SH-SY5Y cells, measurements of AnkG mRNA
levels in various concentrations of miR-342-5p, the mimic of
miR-342-5p (M-miR-342-5p), and the inhibitor of miR-342-5p
(I-miR-342-5p) showed no difference (Figure S1B), suggest-
ing that miR-342-5p likely modulates AnkG levels through
translation repression rather than mRNA degradation. Western
blotting of AnkG with the mimic of miR-342-5p, inhibitor
of miR-342-5p, and mutant miR-342-5p indicated that
miR-342-5p indeed decreased AnkG levels (Figure 2E).
Direct binding of miR-342-5p and AnkG mRNA 30 UTR
was demonstrated by RNase protection assay. A synthesized
miR-342-5p sequence (lane 4) and its antisense reversed
sequence (lane 3) were labeled with 32P probe and mixed
with AnkG mRNA 30 UTR. After RNase digestion, single-
stranded RNAs were degraded, whereas bonded, double-
stranded RNAs remained. Compared with the positive control
(lane 2), where the exact complementary sequence to miR-
342-5p was used, miR-342-5p (lane 4) showed a clear
band (*), suggesting its direct binding to AnkG mRNA 30 UTR
(Figure 2F).266 Cell Reports 6, 264–270, January 30, 2014 ª2014 The AuthorsDownregulation of AnkG in AD Transgenic Mice
Using immunostaining of AnkG, we found that AnkG was ex-
pressed in the axon and highly localized to the AIS in 7 days
in vitro (DIV) WT mouse neurons, whereas the AnkG level was
much lower in APP/PS1 mouse neurons, although localized
AnkG distribution in the AIS remained detectable (Figure 3A).
Western blot data from single-gene transgenic lines indicated
that in PS1 mutated lines, AnkG levels were markedly reduced
(Figure 3B), whereas mRNA levels of AnkG remained un-
changed in various lines (Figure 3F). Western blots further
showed that APP/PS1 mouse neurons had up to a 60% reduc-
tion of the total AnkG level in APP/PS1 mouse neurons at 2,
3, and 5 DIV as compared with WT neurons (Figures 3C and
3D). This reduction was found by using AnkG antibodies from
two different sources (Figure S2A). In adult mice at age of 2,
6, and 8 months, APP/PS1 mouse hippocampal tissues had
lower levels of AnkG compared with WT tissues (Figures 3C
and 3E).
The levels of AnkGmRNA were examined in WT and APP/PS1
mice hippocampal tissues at different ages (Figure S2B). Inter-
estingly, although the protein levels of AnkG in APP/PS1 mice
were lower than in WT mice, the mRNA levels did not show sig-
nificant differencesbetweenWTandAPP/PS1mice (FigureS2B),
suggesting that the downregulation of AnkG in APP/PS1 mice
Figure 3. AnkG Was Downregulated in APP/PS1, PS1DE9, and PS1-M146V Mouse Neurons
(A) Left panel: at 7 DIV, AnkG distributed in the axon in WT mouse neurons, but only slightly in the axon in APP/PS1 mouse neurons. Scale bars, 50 mm (upper
panels) and 10 mm (lower panels). Dashed line, AIS. Right panel: quantification of relative AnkG intensity in WT and APP/PS1 neurons.
(B) AnkG decreased in PS1DE9, PS1-M146V, and APP/PS1 neurons, but not in APPswe or hPS1 neurons. Lane 1: WT; lane 2: APPswe; lane 3: hPS1; lane 4:
PS1DE9; lane 5: PS1-M146V; lane 6: APP/PS1.
(C–E) Western blots (with Invitrogen antibody) show that in neuronal culture at 2, 3, and 5 DIV of E14 embryos and in hippocampal tissues at 0, 2, 6, and 8 months
of age, APP/PS1 mouse neurons and tissues had a smaller amount of AnkG as compared with WT.
(F) The mRNA levels in APPswe, hPS1, PS1DE9, PS1-M146V, and APP/PS1 neurons were not significantly different. Data represent mean ± SE (n = 10 for each
group). **p < 0.01 compared with WT.was due to either accelerated degradation or reduced protein
expression at the translation level.
DISCUSSION
In the present study, we find that miR-342-5p is upregulated in
AD transgenic mice, including APP/PS1, PS1DE9, and PS1-
M146V lines. Furthermore, miR-342-5p binds directly to the
30 UTRof AnkGmRNAand decreases AnkG levels through trans-
lation repression in AD transgenic mouse neurons. miRNA
profiling has been studied in the brain, blood, and CSF of Parkin-
son’s disease patients (Cogswell et al., 2008; He´bert et al., 2008;
Lukiw, 2007, Lukiw et al., 2008; Nelson andWang, 2010; Nunez-
Iglesias et al., 2010; Schipper et al., 2007; Shioya et al., 2010;
Wang et al., 2008) and mouse models (Krichevsky et al., 2003;
Li et al., 2011; Wang et al., 2009; Yao et al., 2010). Using
APPswe/PS1DE9 mouse cortical tissues at 3 and 6 months of
age, Wang et al. (2009) reported 37 differentially expressed
miRNAs, which did not include miR-342-5p (Wang et al., 2009).
The tissue specificity may account for this discrepancy, since
we used hippocampal tissues in this study.
Our data show that PS1 mutation resulted in the most signifi-
cant miR-342-5p upregulation. miR-342-5p is produced by
‘‘dicing’’ its parental miRNA, miR-342 (Westholm and Lai,
2011). To investigate how PS1 mutants increase miR-342-5p
levels, we first examined the parent miR-342 levels in the hippo-
campal tissues from different mouse lines. Our data indicated
that PS1 mutant lines express elevated miR-342 levels (Fig-
ure 4A), suggesting that PS1 mutants might regulate miR-342Cat the transcriptional level. In vitro studies have revealed that
expression of either PS1DE9 or PS1-M146V variants can in-
crease b-catenin levels (Soriano et al., 2001), and indeed, we
also observed a similar upregulation of b-catenin in embryonic
hippocampal tissues from APP/PS1, PS1DE9, and PS1-M146V
mice (Figure 4B). A transcriptional target of b-catenin is c-Myc
(Smalley and Dale, 1999), and we now show that elevated b-cat-
enin expression leads to increased c-Myc levels, which in turn
elevate the levels of interferon regulatory factor 9 (IRF-9), as ex-
pected (Figure 4B; Seitz et al., 2011). miR-342 is localized in the
intron Enah/Vasp-like (EVL) gene (Grady et al., 2008), and it is
known that one of the critical transcription factors that activate
the EVL promoter is IRF-9 (De Marchis et al., 2009). Hence, we
would suggest that elevated IRF-9 leads to an increase in miR-
342 levels. Taken together, our studies indicate that PS1DE9
and PS1-M146V mutants increased miR-342-5p levels through
upregulation of b-catenin, c-Myc, and IRF-9. As the parent
miRNA to miR-342-5p, miR-342 is diced into miR-342-5p and
miR-342-3p (Westholm and Lai, 2011). Given that miR-342 and
miR-342-5p are increased, it is not known why an increase in
another strand, miR-342-3p, is not observed. Probably miR-
342-3p does not successfully bind to the targets as miR-342-
5p does, and then is degraded rapidly.
AnkG has been associated with AIS filtering and protein traf-
ficking (Song et al., 2009). In APP/PS1 mice, axonopathy has
been described as age-dependent axonal spheroids and myelin
ovoids in the spinal cord (Wirths et al., 2006). In PS1mutant mice
(PS1DE9 and PS1-M146V), impaired fast axonal transport has
been demonstrated (Lazarov et al., 2007). It is possible that inell Reports 6, 264–270, January 30, 2014 ª2014 The Authors 267
Figure 4. PS1 Regulated miR-342-5p Levels through b-catenin, c-Myc, and IRF-9
(A) RT-PCR of miR-342 levels in hippocampal tissues from E14 mice of different lines.
(B) Western blots of b-catenin, c-Myc, and IRF-9 in hippocampal tissues from E14 mice of different lines. Lane 1: WT; lane 2: APP/PS1; lane 3: APPswe; lane 4:
hPS1; lane 5: PS1DE9; lane 6: PS1-M146V. Data represent mean ± SE (n = 3 for each group). **p < 0.01 compared with controls.APP/PS1 and PS1 mutant mice, due to downregulation of AnkG
by miR-342-5p, the AIS filtering is impaired, resulting in
abnormal trafficking of proteins. The defective protein trafficking
may induce protein aggregation in the axon, leading to impaired
axonal fast transport. This may contribute to the axonopathy
observed in AD and other neurodegenerative diseases. Finally,
AD has been considered to be an aging-related disorder. Our
data show that developmental defects in miRNA regulation,
AIS filtering, and protein trafficking and localization could be
involved in AD pathogenesis.
EXPERIMENTAL PROCEDURES
Cell Culture, Microinjection, and Treatments
Primary neurons were cultured from E14 APP/PS1 (APPswe/PS1DE9),
APPswe, WT human PS1 knockin (hPS1), PS1DE9, and PS1-M146V mice hip-
pocampus, following the regulations of the Peking University Animal Care and
Use Committee as previously described (Cui et al., 2011). SH-SY5Y cells were
cultured with minimum essential medium (Invitrogen).
miRNA levels were measured by the CapitalBio (Beijing, China) microarray
service using GeneChip miRNA 2.0 (Affymetrix). miR-342-5p in the serum
and CSF was measured with the TaqMan MicroRNA assay kit (Life Technolo-
gies) for Mmu-miR-342-5p according to the manufacturer’s instructions. All
miRNAs were transfected into SH-SY5Y cells with HiPerFect Transfection
Agent (QIAGEN).
RNase Protection Assay
To make the probe, we replaced the 50 end phosphate group of human
miR-342-5p and its reversed control strands with 32P (neg502a001MC;
PerkinElmer) by T4 Polynucleotide Kinase (M0201S; PerkinElmer). The com-
plementary sequence and human AnkG 30 UTR mRNA (50-TTGATAAGGCAC
TGCCTCTTAGAACA-30) were synthesized and purchased from QIAGEN.
The 32P-labeled miR-342-5p, its reversed control or complementary
sequence, and AnkG mRNA 30 UTR were added in the hybridization buffer at
80C for 2 min, and then incubated at 45C for 18 hr. RNase A (D202; Takara)
was added to the sample at 37C for 30 min. The RNAs were purified and run
into 15% PAGE. The gel was dried and revealed by autoradiography.
Immunostaining
Cells were permeabilized in PBS-Triton at 4C, blocked in 10% donkey serum
at room temperature, and then incubated with AnkG antibody (4G3F8,
Invitrogen, 1:200) or MAP2 (Abcam) at 4C for 24 hr. Cy2- or Cy3-conjugated
donkey anti-rabbit antibodies and AMCA-conjugated goat anti-chicken anti-
body were applied as the secondary antibodies. The nuclei were stained
with Hoechst 33258 (1 mg/ml; Sigma) for 15 min in the dark. The coverslips
were mounted with Immunon mounting medium (Shandon) onto glass slides
and the results were analyzed with the use of laser confocal fluorescence
microscope (Leica TCS SP5). A Super Resolution N-SIM Microscope (Nikon)268 Cell Reports 6, 264–270, January 30, 2014 ª2014 The Authorswas used to analyze high-resolution data. The average fluorescence inten-
sities were measured at various distances from the soma area using NIS-
Ements AR software (Nikon). To quantify the data, 15 frames were averaged
with subtraction of background fluorescence intensity.
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